Clinical Trial Update: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating IGIV 10% for mild-to-moderate Alzheimer's disease has been completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• IGIV 10%

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Alzheimer´s Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-10-28